Ultrasonography as a diagnostic tool for sarcopenia in patients with cirrhosis: Examining the pros and cons

Phase angle as a reproducible bedside tool to assess reduced muscle mass in patients with decompensated cirrhosis and ascites: An observational cross-sectional study

BACKGROUND

Reduced muscle mass in patients with cirrhosis is linked to poor clinical outcomes. Bioimpedance analysis estimates fat mass (FM), fat-free mass (FFM), and phase angle (PhA), a marker of cell membrane integrity correlating with computed tomography-based muscle mass assessments. We hypothesized that PhA would remain stable after paracentesis.

METHODS

Bioelectrical impedance was measured in patients with cirrhosis immediately before and after paracentesis using a 256-frequency bioimpedance spectroscopy device. We assessed median paired differences (with 95% confidence intervals) for FM, FFM, and PhA. Reduced muscle mass was diagnosed using PhA thresholds of 5.4 for women and 5.6 for men, based on previous cross-sectional validation against skeletal muscle index.

RESULTS

The study included 32 participants with median age of 60 (IQR: 55-67), 60% male, median model for end stage liver disease Na (MELD-Na) score of 18 (IQR: 14-21), and median paracentesis volume of 6 liters (loss of 5.7 kg). At baseline, 97% had reduced muscle mass based on PhA thresholds. Significant differences were observed between pre-paracentesis and post-paracentesis measurements for FM and FFM (P < 0.05). PhA remained stable (P = 0.208), with a slight nonsignificant increase of 0.1° from pre-paracentesis to post-paracentesis. Sensitivity analysis showed change in reduced muscle mass diagnosis for only one participant.

CONCLUSIONS

FM and FFM levels before and after paracentesis were significantly different, suggesting that these tests would not be accurate in patients with large fluid shifts. PhA measurements were not significantly affected by ascitic fluid shifts after paracentesis, suggesting that PhA may reliably monitor muscle mass in patients, regardless of ascites.

[Thickness of the rectus femorius muscle and vastus intermedium muscle in older Mexican adults with frailty and sarcopenia]

BACKGROUND AND OBJECTIVE

Frailty in older adults is a geriatric syndrome that has gained importance in the last decade. However, there is still no consolidated information regarding diagnostic tools that allow timely identification, and therefore, provide an appropriate therapeutic approach. The objective is to determine the Thickness of the Rectus Femoris Muscle (GMRF) and Thickness of the Vastus Intermedius Muscle (GMVI) in older Mexican adults with frailty and sarcopenia.

MATERIAL AND METHODS

Cross-sectional, descriptive and comparative study in patients ≥65 years of age, admitted to the geriatrics service. The selection was according to the FRAIL (frail vs. non-frail) and SARC-F (high risk vs. low risk) classification; evaluating GMRF and GMVI by ultrasound. The data were analyzed through the statistical software Statistical Package for Social Sciences (SPSS) ver. 25.

RESULTS

The number of patients evaluated in the study and control group were 136 respectively. Significant differences were found regarding frailty status in age (years) (Frail: 75.06±7.92 vs. Non-frail: 71.60±5.56; P<.001), GMRF (mm) (Frail: 8.41±3.08 vs. Non-frail: 11.03±3.50; P<.001) and GMVI (mm) (Frail: 6.53±2.64 vs. Non-frail: 8.66±2.68; P<.001); Considering sarcopenia, there were differences in age (years) (High risk sarcopenia: 75.17±7.84: vs low risk sarcopenia; 71.49±5.60; P<.001), GMRF (mm) (high risk sarcopenia: 8.45±3.11 vs low risk sarcopenia: 10.98±3.50; P<.001) and GMVI (mm) (High risk Sarcopenia: 6.67±2.63 vs Low risk Sarcopenia: 8.52±2.79; P<.001).

CONCLUSIONS

The results found show that there is a significant difference in GMRF and GMVI in Mexican older adults with respect to frailty and sarcopenia. In this way, the present investigation establishes clinical bases for the use of ultrasonography assessments in the geriatric population.

Quantitative Assessment of Body Composition in Cirrhosis

Changes in body composition often accompany the progression of liver disease and seem to be an aggravating pathophysiological factor. Specifically, accelerated loss of skeletal muscle mass, lower muscle quality, and changes in body fat distribution have been shown to be associated with poor clinical outcomes. The aim of the present narrative review was to discuss the current status and relevance of commonly applied, advanced, non-invasive methods to quantify skeletal muscle mass, muscle fat infiltration-i.e., myosteatosis-and fat distribution. This review focuses in particular on Computed Tomography (CT), Dual-energy X-ray Absorptiometry (DXA), Bioelectrical Impedance Analysis (BIA), Magnetic Resonance Imaging (MRI), and Ultrasonography (US). We propose future directions to enhance the diagnostic and prognostic relevance of using these methods for quantitative body composition assessment in patients with cirrhosis.

Screening and assessment of malnutrition in patients with liver cirrhosis

The development and advancement of malnutrition is associated not only with the progression of hepatic dysfunction, but also with cirrhosis-related complications. However, the prevalence of malnutrition reported in different studies varies widely due to differences in diagnostic methods and patient investigation settings. Therefore, we need to identify malnourished patients promptly and accurately. The purpose of this review was to compare the validity and reliability of nutritional screening tools and to select the most appropriate nutritional risk screening for patients with cirrhosis. We compared nutritional risk screening tools such as the Nutritional Risk Screening 2002 (NRS-2002), Malnutrition Universal Screening Tool (MUST), Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) and Liver Disease Undernutrition Screening Tool (LDUST). Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) is more feasible to screen cirrhotic patients for nutritional risk, and is highly reproducible, considering the impact of sodium and water retention; so it is practical to screen cirrhotic patients via RFH-NPT for nutritional risk, subsequently, to evaluate the nutritional status of patients with nutritional risk via the Global Leadership Initiative on Malnutrition (GLIM) diagnostic criteria. L3-SMI (third lumbar-skeletal muscle index) can accurately define sarcopenia in cirrhotic patients and also be used for clinical nutritional status assessment.

Position paper on perioperative management and surgical risk in the patient with cirrhosis

INTRODUCTION

Management of the patient with cirrhosis of the liver that requires surgical treatment has been relatively unexplored. In Mexico, there is currently no formal stance or expert recommendations to guide clinical decision-making in this context.

AIMS

The present position paper reviews the existing evidence on risks, prognoses, precautions, special care, and specific management or procedures for patients with cirrhosis that require surgical interventions or invasive procedures. Our aim is to provide recommendations by an expert panel, based on the best published evidence, and consequently ensure timely, quality, efficient, and low-risk care for this specific group of patients.

RESULTS

Twenty-seven recommendations were developed that address preoperative considerations, intraoperative settings, and postoperative follow-up and care.

CONCLUSIONS

The assessment and care of patients with cirrhosis that require major surgical or invasive procedures should be overseen by a multidisciplinary team that includes the anesthesiologist, hepatologist, gastroenterologist, and clinical nutritionist. With respect to decompensated patients, a nephrology specialist may be required, given that kidney function is also a parameter involved in the prognosis of these patients.

Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution?

Cirrhosis is frequently associated with sarcopenia, with reported rates of over 80% in patients with decompensated alcohol-related liver disease. Sarcopenia negatively impacts the prognosis of cirrhotic patients and affects the response to treatment of patients with hepatocellular carcinoma (HCC). For these reasons, identifying an easy-to-perform method to assess sarcopenia in is a key element in the optimization of care in this patient population. Assessment of muscle mass by computed tomography is considered the standard of care for the diagnosis of sarcopenia, but exposure to radiation and high costs limit its application in this setting, especially for repeated assessments. We believe that ultrasound, a cheap and harmless technique also used for HCC screening in cirrhotic patients, could have an expanding role in the diagnosis and follow-up of sarcopenia in these patients.

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

The condition of sarcopenia, defined as a progressive loss of musculoskeletal mass and muscular strength, is very common in patients with hepatocellular carcinoma (HCC) and presents a remarkable association with its prognosis. Thus, the early identification of sarcopenic patients represents one of the potential new approaches in the global assessment of HCC, and there is increasing interest regarding the potential therapeutic implications of this condition. The gold standard for the quantification of muscle mass is magnetic resonance imaging (MRI) or computed tomography (CT), but these techniques are not always feasible because of the high-cost equipment needed. A new possibility in sarcopenia identification could be muscle ultrasound examination. The measurement of specific parameters such as the muscle thickness, muscular fascicles length or pennation angle has shown a good correlation with CT or MRI values and a good diagnostic accuracy in the detection of sarcopenia. Recently, these results were also confirmed specifically in patients with chronic liver disease. This review summarizes the role of imaging for the diagnosis of sarcopenia in patients with HCC, focusing on the advantages and disadvantages of the diagnostic techniques currently validated for this aim and the future perspectives for the identification of this condition.